A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

Timeline

Start

2022-09-27

Primary completion

2023-06-29

Completion

2023-07-25

Outcome

Met primary endpoint

paper 64% in the 40 mg BID arm vs 0% with placebo (P < .0001). PMID 40659116 ↗

registry analysis (superiority test); ESK-001 40mg BID vs Placebo; p <0.0001; Cochran-Mantel-Haenszel NCT05600036 ↗

Publications

• Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA; STRIDE Investigators. Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study. J Am Acad Dermatol. 2026 Jan;94(1):57-65. doi: 10.1016/j.jaad.2025.07.013. Epub 2025 Jul 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENVUCITINIB	Small molecule	10 mg	Oral
Subject	ENVUCITINIB	Small molecule	40 mg	Oral

Indications